| Autor: |
Chihara, D., Yang, S., Chawla, S. Bains, Zhang, G., Wang, A., Yu, J., Arnette, D., Navarro, F. Rivas, Blaedel, J., Mutebi, A. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p372-373, 2p |
| Abstrakt: |
A new line of therapy (LOT) was defined when next lymphoma directed treatment was started (including retreatment of anti-CD20 mab) after 180 days from completion of previous treatment. Patients experiencing POD24 showed shorter OS than other patients (median OS: 67.5 vs. 103.8 months; hazard ratio [HR] 1.61; 95% CI: 1.46, 1.79). The median EFS becomes shorter with later lines of treatment, indicating unmet needs for effective and tolerable therapies in patients with FL. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text